These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 21702163)
1. [Roles of the cAMP sensor Epac2A in insulin secretion]. Shibasaki T; Seino S Nihon Naika Gakkai Zasshi; 2011 May; 100(5):1418-24. PubMed ID: 21702163 [No Abstract] [Full Text] [Related]
2. Cooperation between cAMP signalling and sulfonylurea in insulin secretion. Shibasaki T; Takahashi T; Takahashi H; Seino S Diabetes Obes Metab; 2014 Sep; 16 Suppl 1():118-25. PubMed ID: 25200305 [TBL] [Abstract][Full Text] [Related]
3. Role of Epac2A/Rap1 signaling in interplay between incretin and sulfonylurea in insulin secretion. Takahashi H; Shibasaki T; Park JH; Hidaka S; Takahashi T; Ono A; Song DK; Seino S Diabetes; 2015 Apr; 64(4):1262-72. PubMed ID: 25315008 [TBL] [Abstract][Full Text] [Related]
4. Treating diabetes today: a matter of selectivity of sulphonylureas. Seino S; Takahashi H; Takahashi T; Shibasaki T Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():9-13. PubMed ID: 22118705 [TBL] [Abstract][Full Text] [Related]
6. Further considerations regarding insulin secretion and metabolism after glipizide treatment. Bonora E; Muggeo M Diabetes Care; 1988 Sep; 11(8):690-2. PubMed ID: 3065008 [No Abstract] [Full Text] [Related]
7. [Physiopathology of non-insulin-dependent diabetes. New therapeutic approaches with gliclazide]. Lesobre B Journ Annu Diabetol Hotel Dieu; 1988; ():337-47. PubMed ID: 3050231 [No Abstract] [Full Text] [Related]
8. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part I--"The pros". Waldhäusl W Horm Metab Res; 1996 Sep; 28(9):517-21. PubMed ID: 8911990 [No Abstract] [Full Text] [Related]
9. [Approaches in diabetes therapy. 2. Selection and use of oral antidiabetics. 1) Drugs enhancing insulin secretion]. Yoshimoto K; Ishida H Nihon Naika Gakkai Zasshi; 2000 Aug; 89(8):1523-9. PubMed ID: 11062899 [No Abstract] [Full Text] [Related]
11. [Pathophysiology of diabetes mellitus type 2 and the mechanism of action and indications for using hypoglycemic sulfonylurea derivatives]. Tatoń J; Koliński P Pol Tyg Lek; 1985 May; 40(18):505-11. PubMed ID: 3892513 [No Abstract] [Full Text] [Related]
12. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Zhang CL; Katoh M; Shibasaki T; Minami K; Sunaga Y; Takahashi H; Yokoi N; Iwasaki M; Miki T; Seino S Science; 2009 Jul; 325(5940):607-10. PubMed ID: 19644119 [TBL] [Abstract][Full Text] [Related]
13. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Ashcroft FM; Gribble FM Diabetologia; 1999 Aug; 42(8):903-19. PubMed ID: 10491749 [No Abstract] [Full Text] [Related]
15. [Effect of long-term therapy with sulfanylurea preparations on the relation of insulin secretion and the insulin-binding capacity of its receptors]. Balabolkin MI; Nedosugova LV Ter Arkh; 1988; 60(12):91-6. PubMed ID: 3150136 [No Abstract] [Full Text] [Related]
16. Differential modulation of Cav1.2 and Cav1.3-mediated glucose-stimulated insulin secretion by cAMP in INS-1 cells: distinct roles for exchange protein directly activated by cAMP 2 (Epac2) and protein kinase A. Liu G; Jacobo SM; Hilliard N; Hockerman GH J Pharmacol Exp Ther; 2006 Jul; 318(1):152-60. PubMed ID: 16565168 [TBL] [Abstract][Full Text] [Related]
17. [Progress in studies on antidiabetic agents]. Tang L; Yang YS; Ji RY Yao Xue Xue Bao; 2001 Sep; 36(9):711-5. PubMed ID: 12580115 [No Abstract] [Full Text] [Related]
18. [Insulinotropic effect of diamicron after oral fructose tolerance test in patients with non-insulin-dependent diabetes mellitus]. Balabolkin MI; Levitskaia ZI; Morozova TP; Zhizhina SA; Gavriliuk LI Probl Endokrinol (Mosk); 1983; 29(5):8-12. PubMed ID: 6359134 [TBL] [Abstract][Full Text] [Related]